{"podcast":{"title":"BioSpace","slug":"biospace-6696251","podcast_index_feed_id":6696251,"rss_url":"https://api.riverside.fm/hosting/3SxyDAXU.rss","website_url":"https://www.biospace.com/","image_url":"https://hosting-media.riverside.com/media/imports/podcasts/a2a52916-bfe1-4f2a-b9a3-9be5029ecbe4/39510587-1699400129885-1e919ae7cb2aa.jpg","author":"BioSpace","episode_count":247,"summary":"Unravel the business of science with BioSpace. We dive into biopharma's top stories and biggest challenges, whether it’s layoffs, pipeline shake-ups, acquisitions, new FDA approvals or how to regulate AI in drug development.","last_synced_at":"2026-07-15T16:19:04.105662+00:00","page_url":"https://stenobird.com/podcast/biospace-6696251"},"episode":{"title":"Funding the Future of European Biotech","slug":"funding-the-future-of-european-biotech","published_at":"2026-04-16T21:26:40+00:00","page_url":"https://stenobird.com/podcast/biospace-6696251/funding-the-future-of-european-biotech","show_page_url":"https://stenobird.com/podcast/biospace-6696251","url":"https://api.riverside.com/hosting-analytics/media/64ecc58072ed70e4cfc30a202812e46483bac6add04eb6f170850689a1ca241d/eyJlcGlzb2RlSWQiOiIzZGRmODhiZC0xMWI0LTQxMzEtYWY4YS0yM2I2Zjk0MGI3ZDciLCJwb2RjYXN0SWQiOiJhMmE1MjkxNi1iZmUxLTRmMmEtYjlhMy05YmU1MDI5ZWNiZTQiLCJhY2NvdW50SWQiOiI2YTE5YWE5ZTExMTVmZWU4NGJlMjI0MTUiLCJwYXRoIjoibWVkaWEvY2xpcHMvNjllMTU3YzgyOWNhNTMyMWJiMDEwOTQ3L2Rhbi1zYW1vcm9kbml0c2t5cy1zdHVkaW8tYTY3azAtY29tcG9zZXItMjAyNi00LTE2X18yMy00Mi0zMi5tcDMifQ==.mp3","audio_url":"https://api.riverside.com/hosting-analytics/media/64ecc58072ed70e4cfc30a202812e46483bac6add04eb6f170850689a1ca241d/eyJlcGlzb2RlSWQiOiIzZGRmODhiZC0xMWI0LTQxMzEtYWY4YS0yM2I2Zjk0MGI3ZDciLCJwb2RjYXN0SWQiOiJhMmE1MjkxNi1iZmUxLTRmMmEtYjlhMy05YmU1MDI5ZWNiZTQiLCJhY2NvdW50SWQiOiI2YTE5YWE5ZTExMTVmZWU4NGJlMjI0MTUiLCJwYXRoIjoibWVkaWEvY2xpcHMvNjllMTU3YzgyOWNhNTMyMWJiMDEwOTQ3L2Rhbi1zYW1vcm9kbml0c2t5cy1zdHVkaW8tYTY3azAtY29tcG9zZXItMjAyNi00LTE2X18yMy00Mi0zMi5tcDMifQ==.mp3","summary":"In this episode of Denatured, you'll be hearing from Edoardo Negroni, co-founder & managing partner at AurorA-TT and Naveed Siddiqi, senior partner, Venture Investments at Novo Holdings. We debate whether Europe’s world-class science can be matched by a truly integrated venture ecosystem—and what it would take, in practice, to get there. Host Jennifer C. Smith-Parker , Director of Insights, BioSpace Guests Edoardo Negroni , Co-Founder & Managing Partner, AurorA-TT Naveed Siddiqi , Senior Partner, Venture Investments, Novo Holdings Disclaimer: The views expressed in this discussion by guests are their own and do not represent those of their organizations.","meta_description":"In this episode of Denatured, you'll be hearing from Edoardo Negroni, co-founder & managing partner at AurorA-TT and Naveed Siddiqi, senior partner, V…","key_points":[],"chapters":[],"topics":[],"duration_seconds":1210,"processing_state":"not_requested","actions":[{"name":"request_transcript","method":"POST","url":"https://stenobird.com/v1/public/podcasts/biospace-6696251/episodes/funding-the-future-of-european-biotech/transcription-requests","description":"Idempotently request low-priority transcript generation for this episode."},{"name":"read_markdown","method":"GET","url":"https://stenobird.com/podcast/biospace-6696251/funding-the-future-of-european-biotech.md","description":"Read the agent-friendly Markdown representation of this episode resource."}]}}